July 1, 2024HemaSphereOpen Access

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study

View Full Paper

Ask AI

Bookmark

Long-term survival in stage-adapted treatment of HIV-associated Hodgkin lymphoma reached a 10-year overall survival of 95.7% for early favorable disease.
Prospective study of 108 patients evaluated stage-adapted chemotherapy with ABVD or BEACOPP baseline, observing complete remission as a strong survival predictor.
Highlights durable efficacy matching HIV-uninfected cohorts, though late relapses and a second primary malignancy in 10 patients warrant extended surveillance.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective multicenter study demonstrates high long-term overall survival in HIV-associated Hodgkin lymphoma, highlighting durable efficacy comparable to uninfected cohorts despite late risks.

Cite This Study

Hentrich et al. (2024) studied this question.

synapsesocial.com/papers/68e61f34b6db6435875b0cd4 https://doi.org/10.1002/hem3.68

View Full Paper

Ask AI

Bookmark

Implication

Prospective multicenter study demonstrates high long-term overall survival in HIV-associated Hodgkin lymphoma, highlighting durable efficacy comparable to uninfected cohorts despite late risks.

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study

Key Points

Discussion

Implication

Cite This Study

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider